Explore

Rapid Read Rapid Read
Cold Spring Harbor Laboratory Scientists Revive Vancomycin to Combat Superbugs

Cold Spring Harbor Laboratory Scientists Revive Vancomycin to Combat Superbugs

Researchers at Cold Spring Harbor Laboratory (CSHL), led by Professor John Moses, have developed a method to restore the effectiveness of vancomycin, a powerful antibiotic that had become less effective against certain drug-resistant bacteria. The team utilized a technique called diversity oriented clicking (DOC) to create a library of over 150 compounds. In collaboration with Scripps Research, they identified a small molecule, pghi-4, which inhibits a bacterial enzyme called secreted antigen A (SagA). This inhibition allows vancomycin to regain its ability to kill drug-resistant strains of E. faecium, a pathogen known for causing severe infections. The research highlights the potential of using existing drugs in combination with new molecules to combat antibiotic resistance.
Rapid Read Rapid Read
Researchers Explore NAD+ Molecule's Potential to Prevent Premature Labor

Researchers Explore NAD+ Molecule's Potential to Prevent Premature Labor

Researchers have identified the molecule NAD+ (nicotinamide adenine dinucleotide) as potentially significant in predicting and possibly preventing premature labor. This molecule, known for its role in energy production and DNA repair, was found to decrease in placental levels as pregnancies near term in both mice and humans. The study, published in Science, demonstrated that depleting NAD+ in mice led to shorter pregnancies, while supplementing it extended the gestation period. This discovery could lead to new methods for monitoring and managing pregnancy risks, particularly for women over 40, who are more prone to preterm births.
Trendline Trendline
Atossa Therapeutics Presents (Z)-Endoxifen Data for McCune-Albright Syndrome

Atossa Therapeutics Presents (Z)-Endoxifen Data for McCune-Albright Syndrome

Atossa Therapeutics Presents (Z)-Endoxifen Data for McCune-Albright Syndrome
Trendline Trendline
IQVIA's Strategy to Enhance Clinical Trial Success Through Early Patient Population Insights

IQVIA's Strategy to Enhance Clinical Trial Success Through Early Patient Population Insights

IQVIA's Strategy to Enhance Clinical Trial Success Through Early Patient Population Insights
Trendline Trendline
Engitix and Lonza Collaborate to Advance ADC Therapies

Engitix and Lonza Collaborate to Advance ADC Therapies

Engitix and Lonza Collaborate to Advance ADC Therapies
Rapid Read Rapid Read
Researchers Explore Low-Dose Lithium for Early Alzheimer's Disease Brain Protection

Researchers Explore Low-Dose Lithium for Early Alzheimer's Disease Brain Protection

Researchers are investigating the potential of low-dose lithium as a treatment to preserve brain networks in the early stages of Alzheimer's disease. A recent study published in Translational Psychiatry highlights the cognitive benefits of lithium, particularly its interaction with the cholinergic system, which is crucial for cognitive function. The study notes that individuals with Alzheimer's and mild cognitive impairment have significantly lower levels of endogenous lithium in their brains. In animal models, lithium supplementation has shown promise in reducing cognitive deficits and neuropathology associated with Alzheimer's. The researchers suggest that lithium's ability to enhance brain connectivity and inhibit cholinesterase activity could be key to its protective effects. Previous studies have shown that lithium can increase levels of glycine and choline, which are important for brain function, in red blood cells, potentially reflecting similar changes in the brain.
Trendline Trendline
Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models
Rapid Read Rapid Read
Researchers Explore NAD+ Molecule's Potential to Prevent Premature Labor

Researchers Explore NAD+ Molecule's Potential to Prevent Premature Labor

Recent research has identified the molecule NAD+ (nicotinamide adenine dinucleotide) as a potential predictor and influencer of premature labor. The study, published in Science, observed that NAD+ levels in placentas drop significantly as pregnancies near term, both in mice and humans. This decline in NAD+ is linked to the onset of labor. Experiments showed that depleting NAD+ in mouse placentas led to shorter pregnancies, while supplementing with NAD+ precursors extended them. This discovery suggests that monitoring NAD+ levels could help identify women at risk of preterm labor and potentially offer a method to prolong pregnancies. However, further studies, particularly in humans, are necessary before any clinical applications can be considered.
Rapid Read Rapid Read
Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy

Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy

Inflammasome Therapeutics has reported positive results from a Phase 2 clinical trial of its investigational drug K8 for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration. The trial demonstrated that K8 significantly slowed the progression of GA and improved visual acuity over a six-month period. The study involved 30 participants with bilateral GA, and the drug was administered as a bioerodible sustained-release intravitreal implant. The 0.7 mg dose cohort showed a 54% reduction in the mean rate of GA growth compared to the control group, and a 4.0-letter mean advantage in best-corrected visual acuity was observed. These results were presented at the American Society of Retina Specialists Annual Meeting in Montreal.
Trendline Trendline
GLP-1 Medications Show Potential to Slow Biological Aging

GLP-1 Medications Show Potential to Slow Biological Aging

GLP-1 Medications Show Potential to Slow Biological Aging
Rapid Read Rapid Read
Viagra Shows Potential in Restricting Cancer Metastasis, Study Finds

Viagra Shows Potential in Restricting Cancer Metastasis, Study Finds

A recent study published in Cancer Research by scientists at the Weizmann Institute of Science has discovered that sildenafil, the active ingredient in Viagra, may help restrict cancer metastasis. The research, led by Dr. Yarden Ariav in Prof. Ayelet Erez's lab, found that sildenafil limits cancer cells' ability to utilize cholesterol, which is crucial for cancer cells to spread and invade other parts of the body. By blocking the enzyme phosphodiesterase type 5 (PDE5), sildenafil increases levels of cGMP, a signaling molecule that disrupts cholesterol transport within cells. This disruption makes it harder for cancer cells to form metastases. The study also suggests that combining sildenafil with statins, which reduce cholesterol production, could enhance the anti-metastatic effect.
Rapid Read Rapid Read
NAD+ Molecule Shows Promise in Preventing Premature Labor, Study Finds

NAD+ Molecule Shows Promise in Preventing Premature Labor, Study Finds

A recent study published in Science suggests that the molecule NAD+ (nicotinamide adenine dinucleotide) may play a crucial role in preventing premature labor. Researchers observed that NAD+ levels in the placenta drop significantly as pregnancy nears its end, both in mice and humans. By manipulating NAD+ levels in mice, they found that depleting it led to shorter pregnancies, while supplementing it extended pregnancy duration. This discovery points to NAD+ as essential for maintaining pregnancy, with its depletion potentially triggering labor. The study builds on previous research linking NAD+ depletion to pregnancy complications like inflammatory preeclampsia.